Gualt
Nuovo Utente
- Registrato
- 4/2/02
- Messaggi
- 549
- Punti reazioni
- 20
8:31AM ARCA biopharma announces patent issued for treating heart failure patients with bucindolol based on genetic testing (ABIO) 2.65 : The co announces that the U.S. Patent and Trademark Office has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing. The patent (USP# 7,678,824) entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting," provides protection in the United States for this novel approach to treating patients with heart failure, one of the largest health care problems in the United States and the rest of the world... On March 25, ARCA submitted a revised clinical study protocol for review under the FDA's Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of Gencaro in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro... If ARCA obtains sufficient funding and FDA approval of the SPA, ARCA currently expects it could begin the proposed clinical trial approximately one year after such funding and approval. The FDA has previously designated as a Fast Track development program the investigation of Gencaro for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.
SI ENTRA.....
SI ENTRA.....